Quest Diagnostics Files 8-K for Reg FD and Exhibits

Ticker: DGX · Form: 8-K · Filed: 2025-03-19T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, financial-reporting

TL;DR

Quest Diagnostics filed an 8-K on 3/19/25 for Reg FD and exhibits.

AI Summary

Quest Diagnostics Incorporated filed an 8-K on March 19, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing details the company's principal executive offices located at 500 Plaza Drive, Secaucus, NJ, 07094, and its telephone number (973) 520-2700. The company was incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing serves as an official record of Quest Diagnostics' regulatory disclosures and financial reporting, providing transparency to investors and the market.

Risk Assessment

Risk Level: low — This filing is a routine regulatory disclosure and does not contain information that inherently increases risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits.

When was this 8-K filed?

This 8-K was filed on March 19, 2025.

Where are Quest Diagnostics' principal executive offices located?

Quest Diagnostics' principal executive offices are located at 500 Plaza Drive, Secaucus, NJ, 07094.

In which state was Quest Diagnostics Incorporated incorporated?

Quest Diagnostics Incorporated was incorporated in Delaware.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

From the Filing

0000947871-25-000317.txt : 20250319 0000947871-25-000317.hdr.sgml : 20250319 20250319083107 ACCESSION NUMBER: 0000947871-25-000317 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250319 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250319 DATE AS OF CHANGE: 20250319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25750937 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 ss4592500_8k.htm CURRENT REPORT false 0001022079 0001022079 2025-03-19 2025-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of Earliest Event Reported) : March 19, 2025   Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)     Delaware (State or other jurisdiction of incorporation) 001-12215   16-1387862 (Commission File Number)   (I.R.S. Employer Identification No.) 500 Plaza Drive     Secaucus , NJ   07094 (Address of principal executive offices)   (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code)         Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 7.01. Regulation FD Disclosure   On March 19, 2025, Quest Diagnostics Incorporated (the “Company”) will host an Investor Day during which members of the leadership team will discuss the Company's strategies to drive sustainable growth and deliver long-term shareholder value.   In connection with Investor Day, the Company issued a press release that, among other things, discusses its business strategy, reiterates its previously issued guidance for full-year 2025 and provides its long-term outlook beyond 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Re

View on Read The Filing